Background: Concerns have been raised that pharmacists sometimes act as barriers to patients with opioid use disorder (OUD) accessing buprenorphine treatment. The present research explores how community pharmacists’ endorsement (vs non-endorsement) of stigmatizing beliefs about patients taking buprenorphine relate to intentions, comfort, and decisions regarding dispensing buprenorphine for OUD. In addition, we assessed attitudes toward risk in pharmacy practice as a novel correlate of dispensing intentions and decisions. Methods: A sample of 207 active community-based pharmacists practicing in the United States responded to survey items measuring stigma, risk tolerance, and intentions to dispense buprenorphine. The survey included 2 vignettes in which patients presented to the pharmacy with a prescription for buprenorphine, and respondents rated their comfort with dispensing and decisions regarding dispensing in the vignette. Results: Results suggest that both stigma toward patients taking buprenorphine to treat OUD and tolerance for risk in pharmacy settings are related to differences in pharmacists’ intentions to and willingness to dispense buprenorphine for OUD. Conclusions: Findings support the need for interventions to reduce stigma associated with buprenorphine use among pharmacists and suggest that risk tolerance is an important determinant of pharmacists’ behavior that merits further study.
- Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample
- Alysson E. Light - University of ChicagoTraci C. Green - Brandeis UniversityPatricia R. Freeman - University of KentuckyParia Sanaty Zadeh - American Pharmacists Association FoundationAnne L. Burns - American Pharmacists Association FoundationLucas G. Hill - The University of Texas at Austin
- Substance Use & Addiction Journal
- 9924321075101921
- Heller School for Social Policy and Management
- English
- Journal article